Do analysts prefer BGLC or MRAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BGLC or MRAI more profitable?

BioNexus Gene Lab has a net margin of -54.70% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat BioNexus Gene Lab's return on equity. Company Net Margins Return on Equity Return on Assets BioNexus Gene Lab -54.70% -37.43% -32.88% Marpai -85.70% N/A -100.23%

Does the media refer more to BGLC or MRAI?

In the previous week, BioNexus Gene Lab had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for BioNexus Gene Lab and 1 mentions for Marpai. BioNexus Gene Lab's average media sentiment score of 0.93 beat Marpai's score of 0.74 indicating that BioNexus Gene Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNexus Gene Lab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Marpai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BGLC or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, BGLC or BMGL?

BioNexus Gene Lab has higher earnings, but lower revenue than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNexus Gene Lab $7.43M 0.74 -$2.98M -$1.48 N/A Basel Medical Group $8.90M 1.38 -$9.50M N/A N/A

Do analysts prefer MGRX or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to MGRX or BGLC?

In the previous week, Mangoceuticals had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 3 mentions for Mangoceuticals and 2 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 0.93 beat Mangoceuticals' score of 0.63 indicating that BioNexus Gene Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mangoceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNexus Gene Lab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BGLC or ACON?

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 114.16%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than BioNexus Gene Lab. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor BGLC or ACON?

In the previous week, Aclarion had 12 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 14 mentions for Aclarion and 2 mentions for BioNexus Gene Lab. Aclarion's average media sentiment score of 0.99 beat BioNexus Gene Lab's score of 0.93 indicating that Aclarion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNexus Gene Lab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclarion 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BRTX or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer BRTX or BGLC?

In the previous week, Biorestorative Therapies and Biorestorative Therapies both had 2 articles in the media. BioNexus Gene Lab's average media sentiment score of 0.93 beat Biorestorative Therapies' score of 0.72 indicating that BioNexus Gene Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNexus Gene Lab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioNexus Gene Lab (BGLC) Competitors

$2.28 -0.02 (-0.87%)

Closing price 04:00 PM Eastern

Extended Trading

$2.25 -0.03 (-1.32%)

As of 07:24 PM Eastern

Compare

BGLC vs. MRAI, BMGL, MGRX, ACON, and BRTX

Should you buy BioNexus Gene Lab stock or one of its competitors? MarketBeat compares BioNexus Gene Lab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioNexus Gene Lab include Marpai (MRAI), Basel Medical Group (BMGL), Mangoceuticals (MGRX), Aclarion (ACON), and Biorestorative Therapies (BRTX). These companies are all part of the "healthcare" industry.

How does BioNexus Gene Lab compare to Marpai?

BioNexus Gene Lab (NASDAQ:BGLC) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

BioNexus Gene Lab has higher earnings, but lower revenue than Marpai. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43M	0.74	-$2.98M	-$1.48	N/A
Marpai	$34.87M	0.39	-$28.75M	-$0.87	N/A

BioNexus Gene Lab has a beta of 4.06, suggesting that its share price is 306% more volatile than the broader market. Comparatively, Marpai has a beta of 4.94, suggesting that its share price is 394% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, BioNexus Gene Lab had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for BioNexus Gene Lab and 1 mentions for Marpai. BioNexus Gene Lab's average media sentiment score of 0.93 beat Marpai's score of 0.74 indicating that BioNexus Gene Lab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNexus Gene Lab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Marpai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioNexus Gene Lab has a net margin of -54.70% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%
Marpai	-85.70%	N/A	-100.23%

Summary

BioNexus Gene Lab and Marpai tied by winning 7 of the 14 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Basel Medical Group?

BioNexus Gene Lab (NASDAQ:BGLC) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

BioNexus Gene Lab has higher earnings, but lower revenue than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43M	0.74	-$2.98M	-$1.48	N/A
Basel Medical Group	$8.90M	1.38	-$9.50M	N/A	N/A

Basel Medical Group has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -54.70%. Basel Medical Group's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%
Basel Medical Group	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

18.9% of BioNexus Gene Lab shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioNexus Gene Lab has a beta of 4.06, meaning that its stock price is 306% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

In the previous week, BioNexus Gene Lab had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 2 mentions for BioNexus Gene Lab and 1 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 1.43 beat BioNexus Gene Lab's score of 0.93 indicating that Basel Medical Group is being referred to more favorably in the news media.

Company	Overall Sentiment
BioNexus Gene Lab	Positive
Basel Medical Group	Positive

Summary

Basel Medical Group beats BioNexus Gene Lab on 6 of the 11 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Mangoceuticals?

Mangoceuticals (NASDAQ:MGRX) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by company insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioNexus Gene Lab has a net margin of -54.70% compared to Mangoceuticals' net margin of -4,639.13%. BioNexus Gene Lab's return on equity of -37.43% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,639.13%	-112.00%	-104.96%
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mangoceuticals has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.06, indicating that its share price is 306% more volatile than the broader market.

BioNexus Gene Lab has higher revenue and earnings than Mangoceuticals. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	14.00	-$20.64M	-$1.49	N/A
BioNexus Gene Lab	$7.43M	0.74	-$2.98M	-$1.48	N/A

In the previous week, Mangoceuticals had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 3 mentions for Mangoceuticals and 2 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 0.93 beat Mangoceuticals' score of 0.63 indicating that BioNexus Gene Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mangoceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNexus Gene Lab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioNexus Gene Lab beats Mangoceuticals on 8 of the 13 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Aclarion?

BioNexus Gene Lab (NASDAQ:BGLC) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 114.16%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than BioNexus Gene Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by insiders. Comparatively, 0.0% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioNexus Gene Lab has higher revenue and earnings than Aclarion. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43M	0.74	-$2.98M	-$1.48	N/A
Aclarion	$80K	107.69	-$7.23M	-$9.03	N/A

In the previous week, Aclarion had 12 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 14 mentions for Aclarion and 2 mentions for BioNexus Gene Lab. Aclarion's average media sentiment score of 0.99 beat BioNexus Gene Lab's score of 0.93 indicating that Aclarion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNexus Gene Lab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclarion	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNexus Gene Lab has a beta of 4.06, suggesting that its stock price is 306% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

BioNexus Gene Lab has a net margin of -54.70% compared to Aclarion's net margin of -10,320.51%. BioNexus Gene Lab's return on equity of -37.43% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%
Aclarion	-10,320.51%	-54.41%	-51.71%

Summary

BioNexus Gene Lab beats Aclarion on 9 of the 16 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Biorestorative Therapies has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.06, indicating that its stock price is 306% more volatile than the broader market.

In the previous week, Biorestorative Therapies and Biorestorative Therapies both had 2 articles in the media. BioNexus Gene Lab's average media sentiment score of 0.93 beat Biorestorative Therapies' score of 0.72 indicating that BioNexus Gene Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNexus Gene Lab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by company insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioNexus Gene Lab has a net margin of -54.70% compared to Biorestorative Therapies' net margin of -3,088.27%. BioNexus Gene Lab's return on equity of -37.43% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

BioNexus Gene Lab has higher revenue and earnings than Biorestorative Therapies. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	24.02	-$14.24M	-$1.07	N/A
BioNexus Gene Lab	$7.43M	0.74	-$2.98M	-$1.48	N/A

Summary

BioNexus Gene Lab beats Biorestorative Therapies on 7 of the 12 factors compared between the two stocks.

Get BioNexus Gene Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGLC vs. The Competition

Export

Metric	BioNexus Gene Lab	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.56M	$8.45B	$6.47B	$12.54B
Dividend Yield	N/A	1.79%	2.69%	5.22%
P/E Ratio	-1.54	22.23	22.39	24.18
Price / Sales	0.74	19.03	520.79	112.26
Price / Cash	N/A	87.48	41.34	57.13
Price / Book	0.64	5.07	9.84	6.72
Net Income	-$2.98M	$178.24M	$3.57B	$337.19M
7 Day Performance	2.70%	-0.90%	-1.16%	0.48%
1 Month Performance	11.76%	3.75%	3.85%	5.07%
1 Year Performance	-33.91%	2.21%	27.40%	34.25%

BioNexus Gene Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGLC BioNexus Gene Lab	0.3877 of 5 stars	$2.28 -0.9%	N/A	-37.8%	$5.56M	$7.43M	N/A	30	Gap Down
MRAI Marpai	N/A	$0.67 +55.8%	N/A	-53.6%	$16.97M	$34.87M	N/A	150
BMGL Basel Medical Group	0.9225 of 5 stars	$0.59 +1.7%	N/A	-86.0%	$10.89M	$8.90M	N/A	36	Positive News Gap Down
MGRX Mangoceuticals	1.1203 of 5 stars	$0.50 -9.5%	N/A	-82.0%	$9.41M	$460K	N/A	3	Gap Down
ACON Aclarion	3.5203 of 5 stars	$3.12 -1.3%	N/A	-47.4%	$7.78M	$80K	N/A	7	Positive News Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGLC) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. MRAI, BMGL, MGRX, ACON, and BRTX

How does BioNexus Gene Lab compare to Marpai?

Summary

How does BioNexus Gene Lab compare to Basel Medical Group?

Summary

How does BioNexus Gene Lab compare to Mangoceuticals?

Summary

How does BioNexus Gene Lab compare to Aclarion?

Summary

How does BioNexus Gene Lab compare to Biorestorative Therapies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. MRAI, BMGL, MGRX, ACON, and BRTX

How does BioNexus Gene Lab compare to Marpai?

Which has better earnings & valuation, BGLC or MRAI?

Which has more risk & volatility, BGLC or MRAI?

Do analysts prefer BGLC or MRAI?

Does the media refer more to BGLC or MRAI?

Do institutionals and insiders have more ownership in BGLC or MRAI?

Is BGLC or MRAI more profitable?

Summary

How does BioNexus Gene Lab compare to Basel Medical Group?

Which has stronger earnings & valuation, BGLC or BMGL?

Is BGLC or BMGL more profitable?

Do analysts recommend BGLC or BMGL?

Do institutionals & insiders hold more shares of BGLC or BMGL?

Which has more volatility and risk, BGLC or BMGL?

Does the media refer more to BGLC or BMGL?

Summary

How does BioNexus Gene Lab compare to Mangoceuticals?

Do institutionals and insiders have more ownership in MGRX or BGLC?

Is MGRX or BGLC more profitable?

Do analysts prefer MGRX or BGLC?

Which has more volatility & risk, MGRX or BGLC?

Which has higher valuation and earnings, MGRX or BGLC?

Does the media refer more to MGRX or BGLC?

Summary

How does BioNexus Gene Lab compare to Aclarion?

Do analysts prefer BGLC or ACON?

Do insiders & institutionals have more ownership in BGLC or ACON?

Which has higher earnings and valuation, BGLC or ACON?

Does the media favor BGLC or ACON?

Which has more volatility and risk, BGLC or ACON?

Is BGLC or ACON more profitable?

Summary

How does BioNexus Gene Lab compare to Biorestorative Therapies?

Which has more volatility & risk, BRTX or BGLC?

Does the media prefer BRTX or BGLC?

Do insiders and institutionals have more ownership in BRTX or BGLC?

Do analysts prefer BRTX or BGLC?

Is BRTX or BGLC more profitable?

Which has better valuation and earnings, BRTX or BGLC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools